EvidioDomingo-MusibayMD
Oncology • Minneapolis, MNMelanoma, Sarcoma
Medical Oncologist, Allina Health Cancer Institute
Dr. Domingo-Musibay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 East 28th Street
Minneapolis, MN 55407- Is this information wrong?
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2012 - 2015- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
University of Minnesota Medical SchoolClass of 2009
Columbia UniversityM.A., Microbiology, 2001 - 2002- Columbia University Vagelos College of Physicians and SurgeonsB.A., Biological Sciences, 2000
Certifications & Licensure
MN State Medical License 2010 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- 28th Annual Short Course on Experimental Models of Human Cancer Jackson Laboratory, 2019
- Merrill J. Egorin Workshop in Cancer Therapeutics and Drug Development Society for Translational Oncology (STO), 2014
Clinical Trials
- Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Start of enrollment: 2018 Jun 22
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.Domingo-Musibay, E., Hieken, T., Nelson, G., Flotte, T., Grewal, E., Chen, J., McWilliams, R., Kottschade, L., Yang, L., Domingo-Musibay, E., Dronca, R., Yan, Y., Mark...> ;Nature Communications. 2024 Feb 16
- 1 citationsMulti-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.Gino K In, Jennifer R Ribeiro, Jun Yin, Joanne Xiu, Matias A Bustos, Fumito Ito, Frances Chow, Gabriel Zada, Lindsay Hwang, April K S Salama, Soo J Park, Justin C Mose...> ;NPJ Precision Oncology. 2023 Nov 14
- 3 citationsSALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J Hauke, Brendan D Curti, Sarah Schober, Mohammed M Milhem...> ;Clinical Cancer Research. 2023 Jun 13
- Join now to see all
Abstracts/Posters
- Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanc...Adi Diab, Mario Marcondes, Brian Kotzin, Mary Ann Tagliaferri, Ute Hoch, Yunfeng Li, Fiore Cattaruzza, Jonathan Zalevsky, Andrew Scott Brohl, James Brugarolas, Mehmet ..., 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 3/1/2019
- Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progressi...Amod Sarnaik, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet Kluger, Jose Lutzky, Melissa Wilson, Anna C. Pavlick, Brendan Curti, Eric Whitman, Karl Le..., ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, 3/2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
